

WINNER STUDY!
AAP CLINICAL
RESEARCH
AWARD 2017



Dr. E. Todd Scheyer,
Houston (USA)
Principal investigator

What was the main focus of this study?

To compare two methods and four materials with an RCT treating severe buccal blow out lesions from perio- and endo- failures. Using an acid test to provide a powerful comparison between two well-known treatment modalities in the USA and Europe.

Which finding of the study impressed you most?

If I had to limit my reply it would be the soft tissue healing and histological outcomes, but the superior horizontal ridge augmentation gain was pretty impressive for the xenograft group.

From your experience: Which aspect of the study is of most relevance for a clinician and his patients?

So many: soft tissue, patient outcomes, histological outcomes, gap wound healing outcomes. Really all we want to know about ridge augmentation in a severe defect model within a human clinical trial.

What makes the study special for you?

With 10 centers, 40 patients, 6 months follow up, cores retrieved and implants placed in 14 months. Then an award winning paper published in less than one year. This has been beyond my dreams when it comes to the big clinical research vision we have at iMc and PHP.

For more information visit:
Mcguireinstitute.org or periohealth.com



Read full paper online
<http://onlinelibrary.wiley.com/doi/10.1111/jcpe.12623/epdf>



More details about our distribution partners:
www.geistlich-biomaterials.com

Geistlich Pharma AG
Business Unit Biomaterials
Bahnhofstrasse 40
6110 Wolhusen, Switzerland
Phone +41 41 492 55 55
Fax +41 41 492 56 39
www.geistlich-biomaterials.com

Affiliate Australia and New Zealand
Geistlich Pharma Australia and New Zealand
The Zenith – Tower A,
Level 19, Suite 19.01
821 Pacific Highway
NSW 2067 Chatswood, Australia
Phone +61 1800 776 326
Fax +61 1800 709 698
info@geistlich.com.au
www.geistlich.com.au

Affiliate Great Britain and Ireland
Geistlich Sons Limited
1st Floor, Thorley House
Bailey Lane
Manchester Airport
Manchester M90 4AB, Great Britain
Phone +44 161 490 2038
Fax +44 161 498 6988
info@geistlich.co.uk
www.geistlich.co.uk

Affiliate North America
Geistlich Pharma North America Inc.
202 Carnegie Center
Princeton, NJ 08540 USA
Phone toll-free +1 855 799 5500
info@geistlich-na.com
www.geistlich-na.com

Distribution Canada
HANSAmEd Ltd.
2830 Argentia Road
Unit 5-8
LSN 8G4 Mississauga, Canada
Phone +1 800 363 2876
Fax +1 800 863 3213
orders@hansamed.net
www.hansamed.net




Geistlich
Biomaterials

LEADING REGENERATION

Geistlich
Biomaterials

Geistlich Bio-Oss® Collagen and Geistlich Bio-Gide® in Extraction Sockets

Key to success



Geistlich Bio-Gide®

Sizes: 25 x 25 mm, 30 x 40 mm



Geistlich Bio-Oss® Collagen

Geistlich Bio-Oss® (small granules) + 10% collagen (porcine) Sizes: 100 mg (0.2 – 0.3 cm³), 250 mg (0.4 – 0.5 cm³), 500 mg (0.9 – 1.1 cm³)



Geistlich Bio-Gide® Compressed

Sizes: 13 x 25 mm, 20 x 30 mm



Geistlich Bio-Gide® Shape

Size: 14 x 24 mm



References

- Scheyer ET et al. J Clin Periodontol. 2016; 43:1188-1199. (clinical)
- Oragraft® DGC, LifeNet Health, Inc., Virginia Beach, VA, USA
- Biomend® Extend; Zimmer Dental, Inc., Carlsbad, CA, USA
- Ghanaati S et al. Acta Biomater. 2012 Aug;8(8):3061-72. (in-vivo)
- Ghanaati S et al. Biomed Mater. 2011 Feb;6(1):015010. (in-vivo)
- Becker J et al. Clin Oral Impl Res. 2009; 20:742-749. (clinical)
- Perelman-Karmon M et al. Int J Periodontics Restorative Dent. 2012; 32(4):459-65. (clinical)
- Bröseler F et al. J Clin Periodontol. 2017; 44:520-529. (clinical)
- Jung R et al. Clin Oral Implants Res. 2013 Oct;24(10):1065-73. (clinical)
- Buser D et al. J Periodontol. 2013 Nov;84(11):1517-27. (clinical)
- Jensen SS et al. J Periodontol. 2014 Nov;85(11):1549-56. (clinical)
- Cardaropoli D et al. Int J Periodontics Restorative Dent. 2012 Aug;32(4):421-430. (clinical)
- Thoma DS et al. J Clin Periodontol. 2017 May;44(5):556-565. (in-vivo)
- Rocuzzo M et al. Int J Periodontics Restorative Dent. 2014 Nov-Dec;34(6):795-804. (clinical)


601752/1709/en © 2017 Geistlich Pharma AG – Subject to modifications



Key to success – Your surgical expertise




Clinical case by Dr. Diego Velasquez I Fenton (USA), Co-author



- 1 Buccal view of extended post-extraction defect with buccal dehiscence in Region 46.
- 2 Complete filling of the socket with Geistlich Bio-Oss® Collagen after debridement to preserve ridge volume.
- 3 Application of Geistlich Bio-Gide® for protection from soft-tissue ingrowth and mechanical dislocation.
- 4 Soft tissue flap is securely closed over the augmented area. Good soft tissue healing at 1 week post-op.
- 5 Buccal view of the preserved ridge at 6 months with good soft tissue status and stable ridge volume.
- 6 Buccal view after flap elevation shows good bony result with successful integration of the bone graft material.

Key to success – our expert products



- 1 Occlusal view of well preserved ridge at 6 months after treatment with Geistlich Bio-Oss® Collagen and Geistlich Bio-Gide® before and after flap elevation.
- 2 Occlusal view of resorbed ridge at 6 months after treatment with an allograft² and a cross-linked membrane³ before and after flap elevation.

1 The treatment of post-extraction alveolar ridge preservation of sockets with substantial buccal dehiscences with Geistlich Bio-Oss® Collagen and Geistlich Bio-Gide® resulted in 35% more horizontal ridge volume with the same new bone formation at 6 months healing time. (Picture 1)

All planned implants can be placed without a re-grafting at implant placement.¹

2 Treatment with the combination of a demineralized allograft² covered with a reconstituted artificially cross-linked collagen membrane³ resulted in lower ridge dimensions (Picture 2) after 6 months, which is statistically significant linked to a higher soft-tissue inflammation on average at 1 week healing time.¹
14% of the planned implants could not be placed without a 2nd re-grafting at implant placement.¹

Pictures by courtesy of Dr. Velasquez

Key to success – Handing over to nature


Geistlich Bio-Gide® – protecting your success

No foreign body reaction including multinucleated giant cells^{4,5}

Significantly more side effects occurred with an extended life collagen membrane such as wound dehiscences or inflammations⁶

Protects your bone graft from soft tissue ingrowth⁶ and mechanical dislocation⁷

Increased volume of regenerated bone under the protection of Geistlich Bio-Gide®^{7,8}



+35%
horizontal volume

Geistlich Bio-Oss® Collagen – grafting a solid foundation

High bone volume stability is crucial for long-term implant survival rate^{9,11}

Considerably reduced horizontal and vertical bone resorption after grafting with Geistlich Bio-Oss® Collagen¹²

Use of Geistlich Bio-Oss® Collagen results in good bone-to-implant contact in the regenerated socket¹³

Geistlich Bio-Oss® granules remain volume stable in the regenerated defect¹⁰


ALTERNATIVE PRODUCTS

GEISTLICH BIOMATERIALS

SOFT-TISSUE HEALING¹



IMPLANT PLACEMENT¹



The combination of the beneficial properties of Geistlich biomaterials results in the same amount of newly formed bone compared to a demineralized allograft² covered with a reconstituted artificially cross-linked collagen membrane^{3,1}. There is no need for a second grafting at re-entry¹. Predictable long-term results after 10 years using Geistlich Bio-Oss® Collagen¹⁴

BONE FORMATION¹

